arrow
R

Richard R. Furman

new york–presbyterian hospital
H指数:75
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

奥加曲沙在瓦尔登斯特伦巨球蛋白血症中,5年随访显示持久应答

2026-04-170
OAAI
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up

接受维奈克拉治疗的BCRi经治CLL患者中复发性基因组改变:扩展的2期随访研究

2026-04-080
OAAI
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia

Acalabrutinib在初治及复发/难治性慢性淋巴细胞白血病中的最终II期研究结果

2026-04-020
OAAI
Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia

B细胞受体与NOTCH1在调控慢性淋巴细胞白血病代谢重编程中的功能协同作用

Leukemia
IF13.4
2026-03-230
OAAI
Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples

临床相关样本中酶法和亚硫酸氢盐DNA甲基化分析的全面比较

2025-10-050
OAAI
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy

代表美国移植与细胞治疗学会发布的关于异基因造血细胞移植和嵌合抗原受体T细胞疗法在慢性淋巴细胞白血病患者中作用的临床实践建议

2025-06-010
OAAI
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry

非洲血统患者慢性淋巴细胞白血病的基因组特征

2025-02-061
OA
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia
2024-12-230
PRE
Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

增强继发性HLH的诊断和预后策略:Weill-Cornell Medicine经验的启示

BLOOD
IF23.1
2024-11-050
PRE
Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC4a1S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

转录组基因分型的话题建模揭示了BTKC4a1S-突变型和野生型细胞在Btki-耐药慢性淋巴细胞白血病中的协同作用

BLOOD
IF23.1
2024-11-050
PRE
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
2024-04-271
OAAI
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
2023-11-1512
OAAI
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
2022-08-0428
OAAI
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
2021-12-2328
OAAI